A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)

Randomized Phase III Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00190515

Enrollment

1101

Registered

2005-09-19

Start date

2003-02-28

Completion date

2011-11-30

Last updated

2016-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasms

Keywords

adjuvant chemotherapy, Stage III colorectal cancer, 5-FU+l-LV, UFT+LV, randomized controlled trial

Brief summary

To evaluate the clinical effectiveness of oral UFT/LV comparing 5-FU/l-LV as adjuvant therapy for stage III colorectal cancer.

Detailed description

Oral fluoropyrimidines are widely used in practice for postoperative adjuvant chemotherapy for curatively resected colorectal cancer in Japan. In order to evaluate a clinical benefit of oral anticancer drugs in adjuvant chemotherapy, we conducted randomized controlled trial comparing the oral combination chemotherapy, UFT+LV, to the standard intravenous combination chemotherapy, 5-FU+l-LV, in stage III colorectal cancer. UFT+LV: UFT 300mg/m2/day and LV 75mg/day, orally for 28days with 7days rest, repeated five times every 5 weeks. 5-FU+l-LV: 5-FU 500mg/m2, l-LV 250mg/m2, weekly administration for 6 times, repeated three times every 8 weeks. Primary endpoints are disease-free survival and secondary endpoints are overall survival and adverse event rate.

Interventions

DRUG5FU+l-leucovorin

5FU+l-leucovorin

DRUGUFT+Leucovorin

UFT+Leucovorin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Pathologically proved colorectal cancer (either adenocarcinoma, mucinous carcinoma, or signet-ring cell carcinoma). 2. Tumor is mainly located in between cecum and upper rectum, excluding that invades to lower rectum. 3. Stage III cancer by General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (6th ed.), excluding si(ai), n(-), M(-). 4. No synchronous colorectal cancer which invade muscularis propria or deeper. 5. Tumor resection with D2 or D3 lymph node dissection was performed. 6. Pathological determination of curability of tumor resection is cur A. 7. Age at registration is above 20 and below 75 years old. 8. ECOG Performance status is 0 or 1. 9. No prior chemotherapy or radiation therapy. 10. Intake of normal diet and oral drugs is possible. 11. Major organ function is preserved. WBC\>=3,000/mcl, PLT\>=100,000/mcl, GOT\<=100 IU/L, GPT\<=100 IU/L, T.Bil \<=2.0 mg/dl, Cr\<=1.5 mg/dl 12. Adjuvant chemotherapy can be started within 9 weeks after surgery. 13. Written informed consent is taken.

Exclusion criteria

1. Active co-existing malignancy （synchronous or metachronous malignancy whose disease free period is within 5 years). Carcinoma in situ is eligible. 2. Severe postoperative complications which do not resolve until registration. 3. There is following complication. insulin-controlling or uncontrollable diabetes mellitus, uncontrollable hypertension, myocardial infarction within six month or unstable angina pectoris, liver cirrhosis, interstitial pneumonia, pulmonary fibrosis, severe emphysema 4. Pregnant or breast-feeding woman. 5. Difficult to participate with the trial, having mental disorder or psychiatric symptoms. 6. Judged to be inappropriate to register.

Design outcomes

Primary

Measure	Time frame
Disease-free survival	during the study conduct

Secondary

Measure	Time frame
Overall survival	during the study conduct
Rate of adverse event	during the study conduct

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026